FTC Warns ‘Junk Patents' Could Make Drugs Like Ozempic Pricier—Here's How [Forbes]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Forbes
claim could increase prices for medications like Novo Nordisk's diabetes drug Ozempic by making it harder to produce generic drugs. The “bogus” patent listings keep brand name drug prices “artificially high,” regulators said. The FTC sent warning letters to 10 pharmaceutical companies—including Novo Nordisk, AstraZeneca, GlaxoSmithKline and Teva—disputing more than 300 “junk” patent listings across 20 different brand name products, the agency Tuesday. Some patents filed by these companies are “bogus” because they aren't related to the drug they sell, like the injection “button” for Novo Nordisk's diabetes drug Victoza or the “injection device with torsion spring and rotatable display” for Ozempic, to the FTC. If “improper or inaccurate” patents appear in the Food and Drug Administration's Orange Book, which lists patents for brand name drugs, cheaper generic alternatives for these drugs are delayed from entering the market, the FTC said, making brand name drug prices remain “a
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Novo Nordisk unsure when it will meet obesity drug demand: report [Seeking Alpha]Seeking Alpha
- Nestlé launches food line targeting Ozempic, other weight-loss drug users [FOX Business Network]FOX Business Network
- Microcap Mangoceuticals doubles on plan to sell cheap oral GLP-1 weight loss meds [Seeking Alpha]Seeking Alpha
- Many Quit Weight-Loss Drugs Too Early for Benefits, Insurer Says [BNN Bloomberg (Canada)]BNN Bloomberg
- Wegovy, Saxenda study reveals surprising trend for weight loss drugs [USA TODAY]USA TODAY
NVO
Earnings
- 5/3/24 - Beat
NVO
Sec Filings
- 5/17/24 - Form 6-K
- 5/17/24 - Form SD
- 5/15/24 - Form 6-K
- NVO's page on the SEC website